Patents by Inventor Britt-Marie Swahn
Britt-Marie Swahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120165347Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: December 20, 2011Publication date: June 28, 2012Applicant: ASTRAZENECA ABInventors: Gabor Csjernyik, Sofia Karlström, Annika Kers, Karin Kolmodin, Martin Nylöf, Liselotte Öhberg, Laszlo Rakos, Lars Sandberg, Fernando Sehgelmeble, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg
-
Patent number: 8193363Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.Type: GrantFiled: August 20, 2009Date of Patent: June 5, 2012Assignee: AstraZeneca ABInventors: Seth Björk, Peter Johnström, Nils Anders Nilsson, Katinka Ruda, Per Magnus Schou, Britt-Marie Swahn, Vern Delisser
-
Publication number: 20120122843Abstract: The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of A?-related diseases.Type: ApplicationFiled: November 9, 2011Publication date: May 17, 2012Applicant: ASTRAZENECA ABInventors: István MACSÁRI, Kim PAULSEN, Laszlo RAKOS, Britt-Marie SWAHN, Magnus WALDMAN, Didier ROTTICCI, Stefan VON BERG
-
Publication number: 20110319426Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: September 6, 2011Publication date: December 29, 2011Applicant: ASTRAZENECA ABInventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
-
Patent number: 8030500Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: GrantFiled: November 13, 2009Date of Patent: October 4, 2011Assignee: AstraZeneca ABInventors: Jörg Holenz, Sofia Karlström, Karin Kolmodin, Johan Lindström, Laszlo Rakos, Didier Rotticci, Peter Söderman, Britt-Marie Swahn, Stefan Von Berg
-
Patent number: 7772256Abstract: The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: GrantFiled: March 5, 2008Date of Patent: August 10, 2010Assignee: Astrazeneca ABInventors: Erwan Arzel, Britt-Marie Swahn, David Wensbo
-
Publication number: 20100125081Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: ASTRAZENECA ABInventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SODERMAN, Marie SUNDSTROM, Britt-Marie SWAHN, Stefan VON BERG
-
Publication number: 20100125087Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: AstraZeneca ABInventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Laszlo RAKOS, Peter SODERMAN, Britt-Marie SWAHN, Stefan VON BERG, Fredrik VON KIESERITZKY
-
Publication number: 20100125082Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.Type: ApplicationFiled: November 13, 2009Publication date: May 20, 2010Applicant: ASTRAZENECA ABInventors: Jörg HOLENZ, Sofia KARLSTRÖM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SÖDERMAN, Britt-Marie SWAHN, Stefan VON BERG
-
Publication number: 20100098631Abstract: The present invention relates to novel 2-heteroaryl substituted indole derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted indole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer?s disease therapeutic agents.Type: ApplicationFiled: March 5, 2008Publication date: April 22, 2010Applicant: ASTRAZENECA ABInventors: Erwan Arzel, Britt-Marie Swahn, David Wensbo
-
Publication number: 20100056796Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.Type: ApplicationFiled: August 20, 2009Publication date: March 4, 2010Applicant: ASTRAZENECA ABInventors: Seth Bjõrk, Peter Johnstrõm, Nils Anders Nilsson, Katinka Ruda, Per Magnus Schou, Britt-Marie Swahn, Vern Delisser
-
Patent number: 7670591Abstract: The present invention relates to novel heteroaryl substituted benzoxazole derivatives and therapeutic uses for such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzoxazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: GrantFiled: June 14, 2007Date of Patent: March 2, 2010Assignee: AstraZeneca ABInventors: Jonas Malmstrom, David Pyring, Can Slivo, Daniel Sohn, Britt-Marie Swahn, David Wensbo
-
Publication number: 20080221149Abstract: The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measureing clinical efficacy of Alzheimer's disease therapeutic agents.Type: ApplicationFiled: March 5, 2008Publication date: September 11, 2008Applicant: AstraZeneca ABInventors: Erwan Arzel, Britt-Marie Swahn, David Wensbo
-
Publication number: 20080027051Abstract: The present invention relates to novel heteroaryl substituted benzoxazole derivatives and therapeutic uses for such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzoxazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measureing clinical efficacy of Alzheimer's disease therapeutic agents.Type: ApplicationFiled: June 14, 2007Publication date: January 31, 2008Applicant: AstraZeneca ABInventors: Jonas Malmstrom, David Pyring, Can Slivo, Daniel Sohn, Britt-Marie Swahn, David Wensbo
-
Publication number: 20050113370Abstract: The invention provides a compound of Formula I Formula I wherein R1 is aryl or heteroaryl each of which is optionally substituted with one or more of the following R3, —OR3, —OCOR3, —COOR3, —COR3, —CONR3R4, —NHCOR3, —NR3R4, —NHSO2R3, —S2R3, —SO2NR3R4, —SR3, CN, halogeno or NO2; R2 is NO2, NH2, —NR5R6 or —NR6R7; as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.Type: ApplicationFiled: February 11, 2003Publication date: May 26, 2005Inventors: Jonas Malmstrom, Britt-Marie Swahn
-
Publication number: 20050075334Abstract: The present invention relates to new compounds of formula (I) wherein R1, R2, R3, R4, R5 and A are defined as in formula (I), a process for their preparation and new intermediate prepared therein, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the treatment of c-Jun N-terminal kinase (JNK) mediated conditions in mammals, particularly Alzheimer's Disease.Type: ApplicationFiled: December 18, 2002Publication date: April 7, 2005Inventors: Sarah King, Simon Teague, Yafeng Xue, Britt-Marie Swahn
-
Patent number: 6774132Abstract: The present invention relates to certain spirooxindole derivatives and to pharmaceutically acceptable salts thereof, which exhibit good analgesic properties and are effective in the treatment of chronic pain. The derivatives have the structure of formula I: wherein: Ar is benzene or pyridine; X is NHCO—; —CONH—; or —NH—SO2—; Y is a single bond; and Z is —CH═CHCH2.Type: GrantFiled: October 27, 2000Date of Patent: August 10, 2004Assignee: AstraZeneca ABInventors: Alf Claesson, Britt-Marie Swahn, Odd-Geir Berge
-
Publication number: 20040087800Abstract: The present invention relates to certain spirooxindole derivatives of the formula I, and pharmaceutically acceptable salts thereof, which exhibit good analgesic properties and are particularly effective in the treatment of chronic pain.Type: ApplicationFiled: October 27, 2003Publication date: May 6, 2004Applicant: AstraZeneca ABInventors: Alf Claesson, Britt-Marie Swahn, Odd-Geir Berge
-
Patent number: 5710139Abstract: Compounds of the formula I, ##STR1## are NMDA antagonists and useful in the treatment and prevention of nervous system related pathological conditions resulting from overstimulation by excitatory amino acids. Methods for their preparation and pharmaceutical compositions containing them are also comprised according to the invention.Type: GrantFiled: February 7, 1995Date of Patent: January 20, 1998Assignee: Astra ABInventor: Britt-Marie Swahn